长江商报消息●长江商报记者 徐佳 并购参股公司旗下资产，开能健康（300272.SZ）将加大对细胞产业的投资力度。 11月24日晚间，开能健康披露资产收购计划，公司全资子公司海南开能细胞拟以现金方式，作价2.04亿 元收购关联方原能集团旗下4家公司股权。 长江商报记者注意到，在"双能驱动"的发展战略下，开能健康意在净水产业的基础上，拓展公司在大健 康领域的产业布局。通过购买原能集团已孵化成熟的项目和资产，开能健康将加强在细胞产业的投资， 并计划将细胞产业打造成为公司第二增长曲线。 财报显示，2025年前三季度，开能健康实现营业收入13.56亿元，同比增长8.1%；归属于上市公司股东 的净利润（以下简称"归母净利润"）9535.32万元，同比增长13.29%。 尽管本次交易并未设置业绩承诺，但开能健康的实控人瞿建国承诺，其将尽最大努力，争取收购完成两 个会计年度内标的公司实现盈利。若2027年度标的公司仍亏损，将由原能集团补足差额，瞿建国对此提 供连带责任担保。 拟并购关联方旗下4家公司 根据交易方案，开能健康的全资子公司海南开能细胞拟以现金方式，收购原能丽水持有的原天生物、丽 水东昕100%股权及原能集团持有 ...

长江商报记者注意到，在"双能驱动"的发展战略下，开能健康意在净水产业的基础上，拓展公司在大健康领域的 产业布局。通过购买原能集团已孵化成熟的项目和资产，开能健康将加强在细胞产业的投资，并计划将细胞产业 打造成为公司第二增长曲线。 财报显示，2025年前三季度，开能健康实现营业收入13.56亿元，同比增长8.1%；归属于上市公司股东的净利润 （以下简称"归母净利润"）9535.32万元，同比增长13.29%。 尽管本次交易并未设置业绩承诺，但开能健康的实控人瞿建国承诺，其将尽最大努力，争取收购完成两个会计年 度内标的公司实现盈利。若2027年度标的公司仍亏损，将由原能集团补足差额，瞿建国对此提供连带责任担保。 拟并购关联方旗下4家公司 根据交易方案，开能健康的全资子公司海南开能细胞拟以现金方式，收购原能丽水持有的原天生物、丽水东昕 100%股权及原能集团持有的克勒猫、基元美业100%股权。 长江商报消息 ●长江商报记者 徐佳 并购参股公司旗下资产，开能健康（300272.SZ）将加大对细胞产业的投资力度。 11月24日晚间，开能健康披露资产收购计划，公司全资子公司海南开能细胞拟以现金方式，作价2.04亿元收购关 ...

标的公司涵盖细胞制备、实验动物服务、细胞技术化妆品等业务，其中，原天生物专注于干细胞、免疫 细胞等多种细胞制备技术及相关细胞试剂产品研发与生产，共获得授权专利44项；丽水东昕为投资持股 平台，未开展实质经营，其子公司上海东昕生物技术有限公司（以下简称"上海东昕"）运营位于上海张 江的"原能细胞医药园"，上海东昕子公司上海莱森原生命科学有限公司提供实验动物饲养、实验技术支 持及一站式动物实验解决方案；基元美业及其子公司专注于皮肤细胞修复与再生技术及相关产品的研发 创新等；克勒猫尚未开展经营。 开能健康在公告中表示，此次收购旨在深化大健康产业布局，打造细胞产业第二增长曲线。本次交易完 成后，公司将正式进入干细胞产业，有利于实现公司大健康行业布局规划，进一步提高综合竞争力和可 持续发展能力，符合公司长远战略发展规划。 本报讯 （记者张文湘 见习记者占健宇）11月25日，开能健康（300272）科技集团股份有限公司（以下 简称"开能健康"）发布公告称，公司全资子公司开能健康细胞产业（海南）有限公司拟以现金方式收购 原能细胞科技集团股份有限公司及原能细胞（丽水）产业发展有限公司持有的四家目标公司100%股 权，本次交易 ...

格隆汇11月24日丨开能健康(300272.SZ)公布，公司的全资子公司海南开能细胞与原能集团及原能丽水 签订《关于原能细胞科技集团股份有限公司子公司之股权收购协议》，海南开能细胞以现金方式收购原 能丽水持有的原天生物、丽水东昕100%股权及原能集团持有的克勒猫、基元美业100%股权。本次交易 不会对公司本年度财务状况及经营成果造成重大影响。 本次交易以符合《证券法》规定的资产评估机构出具的模拟合并主体资产评估报告中的评估结果作为定 价依据，最终确定本次交易标的股权的转让价款为20,381.66万元。本次收购后，公司将持有原天生物、 基元美业、丽水东昕、克勒猫100%股权，公司合并报表范围将新增以上公司及其控股子公司（上海东 昕、莱森原、欧珊尔）。 由于本次交易目标公司均属于原能集团同一控制的主体，在原能集团的合并范围内，因此，本次收购完 成后，上述主体均将被开能健康的细胞业务子公司海南开能细胞控制，收购前后保持同一控制的相互关 系。其次，原天生物、丽水东昕和基元美业同属细胞产业链上下游关系，相互之间存在业务协同，如： 原天生物为基元美业提供细胞因子化妆品的研发支持和原料供应；原天生物为莱森原提供宠物保健抗衰 ...

本次交易以符合《证券法》规定的资产评估机构出具的模拟合并主体资产评估报告中的评估结果作为定 价依据，最终确定本次交易标的股权的转让价款为20,381.66万元。本次收购后，公司将持有原天生物、 基元美业、丽水东昕、克勒猫100%股权，公司合并报表范围将新增以上公司及其控股子公司（上海东 昕、莱森原、欧珊尔）。 格隆汇11月24日丨开能健康(300272.SZ)公布，公司的全资子公司海南开能细胞与原能集团及原能丽水 签订《关于原能细胞科技集团股份有限公司子公司之股权收购协议》，海南开能细胞以现金方式收购原 能丽水持有的原天生物、丽水东昕100%股权及原能集团持有的克勒猫、基元美业100%股权。本次交易 不会对公司本年度财务状况及经营成果造成重大影响。 由于本次交易目标公司均属于原能集团同一控制的主体，在原能集团的合并范围内，因此，本次收购完 成后，上述主体均将被开能健康的细胞业务子公司海南开能细胞控制，收购前后保持同一控制的相互关 系。其次，原天生物、丽水东昕和基元美业同属细胞产业链上下游关系，相互之间存在业务协同，如： 原天生物为基元美业提供细胞因子化妆品的研发支持和原料供应；原天生物为莱森原提供宠物保健抗衰 ...

Core Insights - The company reported steady growth in its performance for the first three quarters of 2025, with a total revenue of 1.356 billion yuan, representing a year-on-year increase of 8.10% [1] - The net profit attributable to shareholders reached 95.3532 million yuan, up 13.29% year-on-year, indicating enhanced profitability [1] - In Q3 alone, the company achieved a revenue of 466 million yuan, a 9.80% increase compared to the same period last year, with a net profit of 25.2074 million yuan, showcasing ongoing business expansion capabilities [1] Business Overview - The company operates as a global provider of comprehensive water treatment solutions, with its main business covering the research, manufacturing, and sales of whole-house water purifiers, whole-house softeners, and commercial drinking water purification machines [1] - During the reporting period, the company experienced robust growth across its terminal business and services, smart manufacturing, and core components, which significantly supported overall performance [1] Strategic Initiatives - The company plans to acquire certain subsidiaries of Yuaneng Group to strengthen its investment and layout in the cell industry, aiming to establish this as a second growth curve [1] - This strategic move not only expands the company's business boundaries but also opens new pathways for future profit growth [1] - The company intends to continue focusing on its core water treatment business while simultaneously advancing its cell industry strategy through ongoing technological innovation and market expansion, enhancing its overall competitiveness [1] - With the support of national health industry policies and the rapid development of the industry, the company is expected to encounter broader development opportunities [1]

Core Viewpoint - The company, Kaineng Health, has signed a framework agreement to acquire all equity and assets of several related companies from Yuaneng Cell Technology Group to strengthen its investment in the cell industry, aiming to establish it as a second growth curve for the company [1] Group 1: Acquisition Details - The acquisition involves cash payment for the complete ownership of Yuaneng Group's subsidiaries, including Yuantian Biological, Jiyuan Meiyu, Kele Cat, and Lishui Dongxin [1] - Post-acquisition, Yuaneng Group will retain its core park assets, cell storage business, and cell deployment business [1] - Yuaneng Group is also responsible for a project related to the "cell automation manufacturing factory" as mandated by a national ministry [1] Group 2: Current Holdings and Future Support - Currently, the company holds a 43.70% stake in Yuaneng Group [1] - The company will continue to support the development of related industries following the acquisition [1]

Core Insights - The article discusses the achievements and future plans of Baoshan District in Shanghai during the "14th Five-Year Plan" period, emphasizing its role as a model for modernization and transformation in the context of Shanghai's development strategy [1][3]. Economic Development - Baoshan's GDP surpassed 210 billion yuan, with an annual growth rate of over 5.7% in retail sales [3][5]. - The district's industrial output reached 260 billion yuan, and fixed asset investment exceeded 240 billion yuan over four years, with industrial investment accounting for 20% [3][5]. - The average annual growth rate of revenue from the service industry was 6.1%, with service sector value added exceeding 70% of the economy [3][5]. Innovation and Technology - R&D investment intensity reached 4.69%, with a 20.3% annual growth in high-tech enterprises [3][4]. - Baoshan established 36 innovation and entrepreneurship incubation platforms and collaborated with major universities to create technology parks, resulting in nearly 300 technology achievements being commercialized [4][5]. Industrial Transformation - The district is focusing on six key industries, including high-end materials and robotics, aiming to create billion-yuan industrial clusters [5][6]. - By mid-2025, Baoshan aims to handle 51% of the national cruise ship arrivals and 70% of passenger traffic, with the launch of the domestically produced cruise ship "Aida·Modu" [5][6]. Urban Development - Baoshan is undergoing significant urban renewal, with projects like the Wu Song Innovation City and the integration of high-speed rail and urban development [7][8]. - The district is enhancing its cultural and recreational offerings, including the establishment of the first cruise-themed cultural complex in the city [7][9]. Social Welfare - Baoshan has been recognized as a national civilized city, improving public services and living conditions through urban digital transformation and community development projects [8][9]. - The district is committed to enhancing the quality of life for residents by focusing on beauty, convenience, culture, and safety [8][9]. Future Vision - By 2030, Baoshan aims to become a leading area for innovation and a vibrant, open, and livable international urban center, contributing to the Yangtze River Delta integration and serving as a strategic space for Shanghai's development [10].

Group 1 - The second Shaanxi Province Cell Industry Innovation Conference was held in Xi'an, focusing on "Focusing on Cell Frontiers, Building a New Industry Journey" and officially unveiled the Shaanxi International Cell Gene Industry Transformation Base [1] - The conference attracted over 10 academicians, nearly 50 industry chain enterprises, and more than 1500 participants, highlighting the growing interest and investment in the cell industry [1] - Four core platforms were launched at the conference, including the National Stem Cell Transformation Resource Library (Northwest Branch) and the Shaanxi Province Cell Drug Innovation Center (in preparation), aiming to create an integrated ecosystem from basic research to clinical transformation and industrial application [1] Group 2 - Shaanxi has gathered over 100 biopharmaceutical companies, forming a complete chain covering storage, research and development, and production [2] - The China Western Innovation Port aims to deepen industry-university-research collaboration and promote the upgrade of the cell industry towards intelligent manufacturing [2] - Shaanxi Province aims to cultivate a trillion-level industrial cluster, striving to become a national innovation source for the cell industry [2]